Tableaux’s Lineage Cell Therapeutics LCTX Stock Holding History

Tableaux’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$28K	Buy	+29,300	New	+$32.4K	0.01%	122

Other funds holding LCTX

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

Hofer & Associates Thousand Oaks, California $143M AUM 11.29% 1-Year Est. Return

Red Crane Wealth Management San Francisco, California $143M AUM 13.63% 1-Year Est. Return

Connecticut Wealth Management Farmington, Connecticut $2.73B AUM 14.39% 1-Year Est. Return

Beirne Wealth Consulting Services Shelton, Connecticut $505M AUM 16.24% 1-Year Est. Return

Chapin Davis Baltimore, Maryland $520M AUM 117.57% 1-Year Est. Return

Axxcess Wealth Management Carlsbad, California $2.44B AUM 16.42% 1-Year Est. Return

Founders Capital Management (Texas) Houston, Texas $220M AUM 46.36% 1-Year Est. Return

Anchyra Partners Atlanta, Georgia $477M AUM 34.33% 1-Year Est. Return

ELCO Management New York $213M AUM 25.22% 1-Year Est. Return

Tableaux's LCTX Position: Q3 2026 in Review

Tableaux opened a new position in Lineage Cell Therapeutics (LCTX) in Q3 2026: 29,300 shares worth $28K. The stake represents 0.01% of the portfolio and ranks #122 among its holdings.

26 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

Tableaux held 29,300 shares of Lineage Cell Therapeutics worth $28K as of Q3 2026.
Lineage Cell Therapeutics was a new Tableaux position in Q3 2026.
Lineage Cell Therapeutics made up 0.01% of Tableaux's portfolio in Q3 2026, its #122 holding.
26 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on Tableaux's 13F filing for Q3 2026, filed 23 Oct 2026.